Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

36.72 9.61

Buy Sell

Overview

Share price change

24h

Current

Min

32.99

Max

36.88

Key metrics
By Trading Economics
Income	10M 32M
Sales	-28M 215M
P/E Sector Avg	13.618 60.149
EPS	0.79
Profit margin	15.084
Employees	293
EBITDA	-2.8M 49M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+38.06% upside

Dividends
By Acuity
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	54M 1.9B
Previous open	27.11
Previous close	36.72

News Sentiment

By Acuity

50%

145 / 340 Ranking in Healthcare

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lip 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

38.06% upside

12 Months Forecast

Average 46.25 USD 38.06%

High 72 USD

Low 29 USD

Based on 8 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Sentiment

By Acuity

145 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.